<DOC>
	<DOCNO>NCT00429377</DOCNO>
	<brief_summary>This study consist 28-week placebo-controlled double-blind inter-group efficacy study steroid refractory Lupus Nephritis patient .</brief_summary>
	<brief_title>Phase 3 Study Tacrolimus ( FK506 ) Lupus Nephritis : A Placebo Controlled , Double-Blind Multicenter , Comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Steroid refractory lupus nephritis 10mg steroid fail control disease activity patient fail reduce amount steroid patient ’ increase amount steroid due side effect Patients start immunosuppressant therapy increase amount immunosuppressant within 12 week prior test drug administration Patients receive cyclophosphamide pul within 24 week prior test drug administration CNS ( Central Nerve System ) Lupus patient hepatic failure patient Serum creatinine ≧1.5mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>lupus nephritis</keyword>
</DOC>